



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 56283

**Title:** IL-1 receptor antagonist enhances the chemosensitivity of Fluorouracil in the treatment of Kras mutated colon cancer

**Reviewer's code:** 02099493

**Position:** Peer Reviewer

**Academic degree:** FEBG, MAMS, MD, PhD

**Professional title:** Associate Professor, Senior Lecturer, Senior Scientist

**Reviewer's Country/Territory:** Netherlands

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-05-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-05-13 09:09

**Reviewer performed review:** 2020-06-03 02:20

**Review time:** 20 Days and 17 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

This is an interesting study of the IL-1 receptor antagonist enhances the chemosensitivity of Fluorouracil in the treatment of Kras mutated colon cancer. In this study, the Western blot was used to detect the continuous activation of NF- $\kappa$ B pathway in colon cancer cell lines. The methods are clearly described, and reasonable. Results are interesting, and in detail. The manuscript is overall well written, however, a minor editing is required.



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 56283

**Title:** IL-1 receptor antagonist enhances the chemosensitivity of Fluorouracil in the treatment of Kras mutated colon cancer

**Reviewer's code:** 01735331

**Position:** Peer Reviewer

**Academic degree:** MBBS, PhD

**Professional title:** Professor, Research Associate, Research Scientist

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-05-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-05-12 10:53

**Reviewer performed review:** 2020-06-03 02:26

**Review time:** 21 Days and 15 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

It has been actively explored in various studies on how to reduce the toxicity of conventional chemotherapeutic drugs and increase the chemical sensitivity to achieve better curative effects of chemotherapy and gain more benefits for patients with life-span colon cancer. Even the current classic chemotherapy plans, including the FOLFOX regimen and FOLFIRI regimen, contain 5-FU as a component for colon cancer treatment. 5-Fluoracil can inhibit the synthesis of adenylate synthetase and interfere with the synthesis of DNA in tumor cells. The growth of cells remained at a low level, and there was more cell apoptosis. In the Kras and P53 gene mutant mice, we found that the activity of NF- $\kappa$ B was down-regulated by inhibiting the IL-1 receptor and could effectively slow down the tumor growth. This study detected that the adeno-chemotherapy of 5-Fluoracil combined with IL-1 Receptor Antagonist can increase the chemo-sensitivity of 5-FU by decreasing the activation of NF- $\kappa$ B pathway and reduce the proliferation of colon cancer cells. The design of the study is very well. Results are interesting and well discussed. Only the manuscript required an editing, both the language and format.